LL-37 (Cathelicidin)

LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.

Mechanism of Action

Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects.

Typical Dosage (Research)

Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections.

Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols.

Side Effects & Risks

Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses.

May overstimulate immune system in autoimmune conditions. Limited human research data. Quality and purity concerns with research products.

Who Uses LL-37 (Cathelicidin)

Those seeking antimicrobial support, individuals with chronic infections, biohackers focused on immune optimization.